Can Illumina’s Bold Protein Analysis Strategy Reverse Its Market Slide?

Genomics leader Illumina finds itself navigating a complex strategic landscape. The company’s latest quarterly results reveal continued revenue pressure, even as it makes a substantial strategic pivot toward the emerging field of proteomics. This billion-dollar expansion into protein analysis represents a critical gamble to stabilize its financial performance and reverse a significant stock decline.

Strategic Acquisitions and Product Launches

Illumina is countering its challenges with decisive strategic moves. This week, the company unveiled “Illumina Protein Prep,” an innovative platform capable of measuring 9,500 human protein targets—representing the highest capacity currently available using next-generation sequencing (NGS) technology. This launch forms part of a broader expansion strategy:

• A planned acquisition of SomaLogic for up to $425 million aims to significantly strengthen Illumina’s position in the growing proteomics market
• The acquisition process is expected to conclude during the first half of 2026
• Concurrently, the global rollout of “TruSight Oncology 500 v2” will commence in mid-2025, featuring enhanced coverage for cancer research applications

Quarterly Performance: Mixed Results Despite Earnings Beat

The company’s second-quarter results, released July 31, 2025, presented a contrasting picture. While Illumina surpassed expectations with adjusted earnings of $1.19 per share and an operating margin of 23.8%, revenue declined by 3% year-over-year to $1.06 billion. Investors responded negatively to this mixed performance, with shares dropping more than 4% on the day of announcement.

Should investors sell immediately? Or is it worth buying Illumina?

Revised Guidance Fails to Restore Confidence

In a modest positive development, Illumina has slightly upgraded its full-year outlook. The company now anticipates revenue contraction of 2.5-0.5%, improved from previous guidance of 3-1% decline. Adjusted earnings per share are projected between $4.45 and $4.55, up from the earlier range of $4.20-4.30.

Despite these adjustments and a substantial $380 million stock repurchase executed in the second quarter, investor confidence remains fragile. Year-to-date, the stock has declined over 30%, trading approximately 40% below its 52-week high.

Market analysts remain divided on Illumina’s prospects, with price targets ranging from $75 to $200 per share. This wide dispersion reflects uncertainty regarding whether the proteomics initiative can effectively address the structural challenges facing Illumina’s core business. The coming quarters will determine whether this multibillion-dollar multiomics strategy can deliver the anticipated turnaround or if the downward trend will persist.